HCHakki Cetinkaya

Hakki Cetinkaya

*This is an algorithmically generated author record based on publicly available information.

Hakki Cetinkaya has a total of 118 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The Effect of Education Using the Teach‐Back Method on Symptoms of Depression in Hemodialysis Patients

    by Elif Acar, Semiha Akin Eroglu, Busra Zehra Buyukkilic, Besey Oren, Hakki Cetinkaya

    Background: Recently, the Teach‐Back Method has gained recognition in the literature as a promising, evidence‐based strategy for patient education. Objective: This study aimed to assess the impact of individualized education delivered via the Teach‐Back Method on depression levels among adult patients with kidney failure undergoing hemodialysis. Methods: A parallel‐group trial with a pre‐test and post‐test design was conducted. The sample comprised 40 hemodialysis patients. Baseline (pre‐test) data were collected from all participants. The intervention group received individualized education using the Teach‐Back Method, delivered across three sessions. A post‐test was administered 12 weeks after the initial assessment. Results: Pre‐test depression scores were comparable between the intervention and control groups (mean = 13.35 and 13.55, respectively), reflecting mild depression. Following the intervention, the mean depression score in the intervention group decreased significantly to 6.20, indicating a reduction below the mild depression threshold. Conversely, the control group's post‐test score increased to 16.40, remaining within the mild depression range. Conclusion: These findings suggest that Teach‐Back education may reduce depression levels in hemodialysis patients. However, given the small sample size and relatively short follow‐up period, larger studies with longer follow‐up are needed to confirm these findings. Trial Registration: NCT 07069634

  • Open Access

    Immunosuppressive treatment results in patients with primary IgA nephropathy in Turkiye; the data from TSN-GOLD working group

    by Aysegul Oruc, Abdullah Sumnu, Aydın Turkmen, Taner Basturk, Egemen Cebeci, Kenan Turgutalp, Hakkı Cetinkaya, Müge Uzerk Kibar, Nurhan Seyahi, Erhan Tatar, et al.

    Immunoglobulin A (IgA) nephropathy (IgAN) treatment consists of maximal supportive care and, for high-risk individuals, immunosuppressive treatment (IST). There are conflicting results regarding IST. Therefore, we aimed to investigate IST results among IgAN patients in Turkiye. The data of 1656 IgAN patients in the Primary Glomerular Diseases Study of the Turkish Society of Nephrology Glomerular Diseases Study Group were analyzed. A total of 408 primary IgAN patients treated with IST (65.4% male, mean age 38.4 ± 12.5 years, follow-up 30 (3-218) months) were included and divided into two groups according to treatment protocols (isolated corticosteroid [CS] 70.6% and combined IST 29.4%). Treatment responses, associated factors were analyzed. Remission (66.7% partial, 33.7% complete) was achieved in 74.7% of patients. Baseline systolic blood pressure, mean arterial pressure, and proteinuria levels were lower in responsives. Remission was achieved at significantly higher rates in the CS group (78% vs. 66.7%, p = 0.016). Partial remission was the prominent remission type. The remission rate was significantly higher among patients with segmental sclerosis compared to those without (60.4% vs. 49%, p = 0.047). In the multivariate analysis, MEST-C S1 (HR 1.43, 95% CI 1.08-1.89, p = 0.013), MEST-C T1 (HR 0.68, 95% CI 0.51-0.91, p = 0.008) and combined IST (HR 0.66, 95% CI 0.49-0.91, p = 0.009) were found to be significant regarding remission. CS can significantly improve remission in high-risk Turkish IgAN patients, despite the reliance on non-quantitative endpoints for favorable renal outcomes. Key predictors of remission include baseline proteinuria and specific histological markers. It is crucial to carefully weigh the risks and benefits of immunosuppressive therapy for these patients.


  • Could mesangial C3 deposition be an independent prognostic marker in immunoglobulin A nephropathy?

    by Hakki Cetinkaya, Meltem Gursu, Halil Yazici, Egemen Cebeci, Necmi Eren, Mehmet Riza Altiparmak, Omer Faruk Akcay, Gulizar Sahin, Hamad Dheir, Taner Basturk, et al.

    Background Immunoglobulin A nephropathy (IgAN) is a common primary glomerulonephropathy. There is evidence that mesangial C3 deposition plays a role in the development of the disease. The aim of this study was to examine the effect of C3 deposition on the prognosis of IgAN patients. Method The study included 1135 patients with biopsy-confirmed IgAN from the database of the Turkish Nephrology Association Glomerular Diseases Working Group (TSN-GOLD). Patients were excluded from the study if they were aged < 18 or > 75 years or if C3 staining had not been performed in the immunofluorescent analysis. C3 deposition was defined as an immunofluorescence intensity of C3 ≥ 2 + within the mesangium. The primary endpoints were the development of end-stage renal disease, a 30% decrease in glomerular filtration rate compared to the basal value or an elevation in proteinuria to a nephrotic level (3.5 gr/day). Results Mesangial C3 deposition was observed in 603 (53.1%) patients. No statistically significant difference was found at baseline between the groups with and without mesangial C3 deposition, as for age, sex, BMI, proteinuria level, or the presence of hypertension. In the follow-up period with a mean duration of 78 months, no significant difference was found between the two groups regarding the primary endpoints (p = 0.43). A significant correlation between C3 deposition and segmental glomerulosclerosis (S1) according to the Oxford MEST-C classification was found (p = 0.001). Conclusion Although a correlation was observed between mesangial C3 deposition and the S1 MEST-C classification, mesangial C3 deposition was not a prognostic factor in IgAN. Graphical abstract


  • Open Access

    Impact of hospital-acquired acute kidney injury on Covid-19 outcomes in patients with and without chronic kidney disease: a multicenter retrospective cohort study

    by Savaş ÖZTÜRK, Kenan Turgutalp, Mustafa Arici, Hakkı ÇETİNKAYA, Mehmet Rıza Altiparmak, Zeki Aydin, Zeki Soypaçaci, Feyza Bora, Ekrem Kara, Egemen Cebeci̇, et al.

    AAbstract Background/aim: Hospital-acquired acute kidney injury (HA-AKI) may commonly develop in Covid-19 patients and is expected to have higher mortality. There is little comparative data looking for the effect of HA-AKI on mortality of chronic kidney disease (CKD) patients and a control group of general population suffering from Covid-19. HA-AKI development was assessed in a group of stage 3-5 CKD patients and control group without CKD among adult patients hospitalized for Covid-19. The role of AKI development on the outcome (in-hospital mortality and admission to the intensive care unit [ICU]) of patients with and without CKD was compared. Among 621 hospitalized patients (age 60 [IQR:47-73]), women: 44.1%), AKI developed in 32.5% of the patients, as stage 1 in 84.2%, stage 2 in 8.4% and, stage 3 in 7.4%. AKI developed in 48.0 % of CKD patients, whereas in 17.6% of patients without CKD. CKD patients with HA-AKI had the highest mortality rate of 41.1 % compared to 14.3 % of patients with HA-AKI but no CKD (p<0.001). However, patients with AKI+non-CKD had similar rates of ICU admission, mechanical ventilation, and death rate as patients with CKD without AKI. Adjusted mortality risk of the AKI+non-CKD group (HR: 9.0, 95%CI:1.9-44.2) and AKI+CKD group (HR: 7.9, 95%CI:1.9-33.3) were significantly higher than non-AKI+non-CKD group. AKI frequently develops in hospitalized patients due to Covid-19 and is associated with high mortality. HA-AKI has worse outcome whether it develops in patients with or without CKD, but the worst outcome was seen in AKI+CKD patients.


  • Open Access

    Chronic kidney disease predicts poor outcomes of COVID-19 patients

    by Mahmut Gok, Hakki Cetinkaya, Tugba Kandemir, Erdem Karahan, İzZet Burak Tuncer, Cengiz Bukrek, Gulizar Sahin

    Purpose: The recent outbreak of COVID-19 rapidly spread worldwide. Comorbid diseases are determinants of the severity of COVID-19 infection and mortality. The aim of this study was to explore the potential association between chronic kidney disease (CKD) and the severity of COVID-19 infection. Methods: The study included 609 consecutive adult patients (male: 54.52%, mean age: 59.23 ± 15.55 years) hospitalized with the diagnosis of COVID-19 in a tertiary level hospital. Data were collected from the electronic health records of the hospital. The patients were separated into two groups: Group I included COVID-19-positive patients with CKD stage 1–2, and Group II included COVID-19-positive with CKD stage 3–5. The relationships were examined between CKD stage, laboratory parameters and mortality. Results: Significant differences were determined between the groups in respect of the inflammation parameters and the parameters used in prognosis. In Group II, statistically significantly higher rates were determined of comorbid diseases [hypertension (p < 0.001) and diabetes mellitus (p < 0.001), acute kidney injury (AKI), which was found to be associated with mortality (p < 0.001), and mortality (p < 0.001)]. In multivariate regression analysis, CKD stage 3–5, AKI, male gender, hypertension, DM and malignancy were found to be significant independent variables increasing mortality. Conclusion: The prevelance of CKD stage 3–5 on admission is associated with a high risk of in-hospital mortality in patients with COVID-19. Close follow-up can be recommended for patients with a reduced glomerular filtration rate (GFR).


  • P0459ADULT MINIMAL CHANGE DISEASE IN TURKEY: THE RESULTS OF TURKISH SOCIETY OF NEPHROLOGY GLOMERULAR DISEASES WORKING GROUP

    by Mürvet Yılmaz, Murat Sipahioğlu, Erkan Dervişoğlu, Nihal Aydemir, Sami Uzun, Zulal Istemihan, Oktay Unsal, Erhan Tatar, Hacı Bayram Berktas, Arzu Ozdemir Kayalar, et al.

    Background and Aims: Minimal change disease (MCD) is the most common cause of the nephrotic syndrome (NS) in children. Although there are many data regarding the course, response to treatment, and outcomes in pediatric patients, only a few series have examined these issues in adults. The aim of the study was to delineate the demographic and clinical properties of MCD of adult population in our country. Method: All over the country, a total of 47 centers entered data between May 2009 and May 2019 to the database created by of Turkish Society of Nephrology Glomerular Diseases (TSN-GOLD) Working Group. Demographic and clinical characteristics and biopsy findings recorded to the database were analyzed. Results: In total, 258 patients were compatible with the pathological diagnosis of MCD. Mean age was 36.16±15.44 years and 53.88% were male. At diagnosis, 66.7% patients presented with pretibial edema,15.9% with hypertension. Microscopic hematuria occured in 18.2% patients. Only 24 patients (9.3%) presented with a decrease in renal function (serum creatinine greater than 1.3 mg/dl). The mean daily proteinuria was 6.3 g, and serum albumin was 2.6 mg/dl. The most frequent indication for biopsy was NS (86.4%). On kidney biopsy, the mean number of glomeruli was 18.08±11.11. Mezangial proliferation and mezangial IgM were present in 27.5% and 22.5%, respectively. Only in 3.5% of the included patients, electron microscopic studies were performed. Conclusion: This study describes the characteristics of a cohort of adult patients with MCD. MCD in adults may sometimes present concurrently with hematuria, hypertension, and acute kidney injury.

  • Open Access

    The role of plasma triglyceride/high-density lipoprotein cholesterol ratio to predict cardiovascular outcomes in chronic kidney disease

    by Alper Sonmez, Mahmut Ilker Yilmaz, Mutlu Saglam, Hilmi Umut Unal, Mahmut Gok, Hakki Cetinkaya, Murat Karaman, Cem Haymana, Tayfun Eyileten, Yusuf Oguz, et al.

    Cardiovascular disease (CVD) risk is substantially increased in subjects with chronic kidney disease (CKD). The Triglycerides (TG) to High-Density Lipoprotein Cholesterol (HDL-C) ratio is an indirect measure of insulin resistance and an independent predictor of cardiovascular risk. No study to date has been performed to evaluate whether the TG/HDL-C ratio predicts CVD risk in patients with CKD. A total of 197 patients (age 53 ± 12 years) with CKD Stages 1 to 5, were enrolled in this longitudinal, observational, retrospective study. TG/HDL-C ratio, HOMA-IR indexes, serum asymmetric dimethyl arginine (ADMA), high sensitivity C-reactive protein (CRP), parathyroid hormone (PTH), calcium, phosphorous, estimated glomerular filtration rate (eGFR), and albumin levels were measured. Flow mediated vasodilatation (FMD) of the brachial artery was assessed by using high-resolution ultrasonography. A total of 11 cardiovascular (CV) deaths and 43 nonfatal CV events were registered in a mean follow-up period of 30 (range 9 to 35) months. Subjects with TG/HDL-C ratios above the median values (>3.29) had significantly higher plasma ADMA, PTH, and phosphorous levels (p = 0.04, p = 0.02, p = 0.01 respectively) and lower eGFR and FMD values (p = 0.03, p < 0.001 respectively). The TG/HDL-C ratio was an independent determinant of FMD (β = −0.25 p = 0.02) along with TG, HDL-C, hsCRP, serum albumin, phosphate levels, systolic blood pressure, PTH, eGFR and the presence of diabetes mellitus. The TG/HDL-C ratio was also a significant independent determinant of cardiovascular outcomes [HR: 1.36 (1.11-1.67) (p = 0.003)] along with plasma ADMA levels [HR: 1.31 (1.13-1.52) (p < 0.001)] and a history of diabetes mellitus [HR: 4.82 (2.80-8.37) (p < 0.001)]. This study demonstrates that the elevated TG/HDL-C ratio predicts poor CVD outcome in subjects with CKD. Being a simple, inexpensive, and reproducible marker of CVD risk, the TG/HDL-C ratio may emerge as a novel and reliable indicator among the many well-established markers of CVD risk in CKD. Clinical trial registration number and date: NCT02113462/10-04-2014.